pirarubicin and naftopidil

pirarubicin has been researched along with naftopidil* in 1 studies

Other Studies

1 other study(ies) available for pirarubicin and naftopidil

Article	Year
Identification of HUHS190, a human naftopidil metabolite, as a novel anti-bladder cancer drug. Bioorganic & medicinal chemistry letters, 2020, 01-01, Volume: 30, Issue:1 We carried out structure-activity relationship study on anti-cancer effects of naftopidil (1) and its metabolites, resulted in identification of 1-(4-hydroxy-2-methoxyphenyl)piperazin-1-yl)-3-(naphthalen-1-yloxy) propan-2-ol (2, HUHS190), a major human metabolite of 1, which exhibited the most selective toxicities between against normal and cancer cells (Table 1). 2 was more hydrophilic compared to 1, was enough to be prepared in high concentration solution of more than 100 μM in saline for an intravesical instillation drug. Moreover, serum concentration of 2 was comparable to that of 1, an oral preparation drug, after oral administration at 32 mg/kg (Fig. 3). Both of 1 and 2 showed broad-spectrum anti-cancer activities in vitro, for example, 1 and 2 showed inhibitory activity IC Topics: Animals; Antineoplastic Agents; Female; Humans; Male; Mice; Naphthalenes; Piperazines; Structure-Activity Relationship; Urinary Bladder Neoplasms	2020

Article

Year

Identification of HUHS190, a human naftopidil metabolite, as a novel anti-bladder cancer drug.

Bioorganic & medicinal chemistry letters, 2020, 01-01, Volume: 30, Issue:1

We carried out structure-activity relationship study on anti-cancer effects of naftopidil (1) and its metabolites, resulted in identification of 1-(4-hydroxy-2-methoxyphenyl)piperazin-1-yl)-3-(naphthalen-1-yloxy) propan-2-ol (2, HUHS190), a major human metabolite of 1, which exhibited the most selective toxicities between against normal and cancer cells (Table 1). 2 was more hydrophilic compared to 1, was enough to be prepared in high concentration solution of more than 100 μM in saline for an intravesical instillation drug. Moreover, serum concentration of 2 was comparable to that of 1, an oral preparation drug, after oral administration at 32 mg/kg (Fig. 3). Both of 1 and 2 showed broad-spectrum anti-cancer activities in vitro, for example, 1 and 2 showed inhibitory activity IC

Topics: Animals; Antineoplastic Agents; Female; Humans; Male; Mice; Naphthalenes; Piperazines; Structure-Activity Relationship; Urinary Bladder Neoplasms

2020